ARCHIVES

“Harm-Reduction” Products No Proven, IOM Report Says.

This article is from The Cancer Letter archive.

Vol. 27 No. 09 | March 2, 2001

Download PDF Visit The Full Archive

Related Articles

Cancer Meetings Listed For May and June

April 23, 1993

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

May 7, 2004

Penn Begins Clinical Trial Of A Vaccine For Breast Cancer Based On Telomerase

February 27, 2004

Alternative to Animal Use In Research Outlined By OTA

February 21, 1986

Foundation Honors Three In Oncology; Society Wins Software Grant From Microsoft.

October 26, 2001

Karlan To Succeed Hoskins As Chairman, DOD Ovarian Cancer Program Advisory Panel.

July 27, 2001